Certified by Founder Lodge
Immunai
United States - New York, NY
START UP
1 Disclosed Funding Rounds $215,000,000
0 Participating Investments
-
Founded date
2019
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| October, 28 ,2021 | Series B | $215,000,000 |
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
EnerVenue | $300,000,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
